FY2027 EPS Estimates for Labcorp Reduced by Leerink Partnrs

Labcorp Holdings Inc. (NYSE:LH) – Stock analysts at Leerink Partnrs dropped their FY2027 earnings per share estimates for Labcorp in a research note issued on Tuesday, July 8th. Leerink Partnrs analyst M. Cherny now anticipates that the medical research company will post earnings per share of $19.74 for the year, down from their previous estimate of $19.91. The consensus estimate for Labcorp’s current full-year earnings is $16.01 per share.

Labcorp (NYSE:LH) last announced its earnings results on Tuesday, April 29th. The medical research company reported $3.84 earnings per share for the quarter, beating the consensus estimate of $3.73 by $0.11. The firm had revenue of $3.35 billion during the quarter, compared to the consensus estimate of $3.41 billion. Labcorp had a return on equity of 15.27% and a net margin of 5.55%. The firm’s revenue for the quarter was up 5.3% compared to the same quarter last year. During the same quarter in the prior year, the company earned $3.68 EPS.

Other equities research analysts also recently issued reports about the company. Robert W. Baird lifted their target price on Labcorp from $253.00 to $267.00 and gave the stock an “outperform” rating in a research report on Wednesday, April 30th. Truist Financial raised their price objective on Labcorp from $274.00 to $290.00 and gave the stock a “buy” rating in a research report on Monday, May 12th. Wall Street Zen downgraded Labcorp from a “buy” rating to a “hold” rating in a research report on Friday, April 18th. Evercore ISI boosted their price objective on Labcorp from $260.00 to $285.00 and gave the company an “outperform” rating in a research report on Wednesday. Finally, Barclays restated a “cautious” rating on shares of Labcorp in a research note on Wednesday, June 25th. One investment analyst has rated the stock with a sell rating, four have given a hold rating, nine have given a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, Labcorp presently has an average rating of “Moderate Buy” and an average price target of $276.38.

Labcorp Stock Performance

NYSE:LH opened at $253.17 on Thursday. The firm’s 50-day moving average is $253.62 and its 200-day moving average is $242.95. The company has a market cap of $21.19 billion, a price-to-earnings ratio of 29.27, a PEG ratio of 1.64 and a beta of 0.82. The company has a debt-to-equity ratio of 0.68, a quick ratio of 1.60 and a current ratio of 1.84. Labcorp has a 52-week low of $200.90 and a 52-week high of $265.72.

Institutional Investors Weigh In On Labcorp

A number of large investors have recently bought and sold shares of LH. Golden State Wealth Management LLC lifted its position in Labcorp by 88.1% during the 1st quarter. Golden State Wealth Management LLC now owns 111 shares of the medical research company’s stock worth $26,000 after buying an additional 52 shares in the last quarter. Graney & King LLC bought a new position in shares of Labcorp in the fourth quarter worth about $26,000. North Capital Inc. acquired a new position in shares of Labcorp during the first quarter worth approximately $27,000. TruNorth Capital Management LLC bought a new stake in shares of Labcorp during the first quarter valued at approximately $28,000. Finally, Larson Financial Group LLC increased its holdings in shares of Labcorp by 140.4% in the first quarter. Larson Financial Group LLC now owns 125 shares of the medical research company’s stock valued at $29,000 after purchasing an additional 73 shares in the last quarter. 95.94% of the stock is currently owned by institutional investors.

Insider Activity at Labcorp

In related news, Director Kerrii B. Anderson sold 500 shares of the stock in a transaction dated Tuesday, July 1st. The shares were sold at an average price of $265.00, for a total transaction of $132,500.00. Following the completion of the sale, the director owned 12,166 shares in the company, valued at $3,223,990. This trade represents a 3.95% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, EVP Der Vaart Sandra D. Van sold 1,900 shares of the business’s stock in a transaction dated Thursday, May 1st. The shares were sold at an average price of $238.36, for a total transaction of $452,884.00. Following the completion of the transaction, the executive vice president owned 2,244 shares in the company, valued at approximately $534,879.84. This trade represents a 45.85% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders sold 11,834 shares of company stock valued at $2,928,714. Insiders own 0.84% of the company’s stock.

Labcorp Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, September 11th. Shareholders of record on Thursday, August 28th will be issued a dividend of $0.72 per share. This represents a $2.88 dividend on an annualized basis and a dividend yield of 1.14%. Labcorp’s payout ratio is presently 33.29%.

Labcorp Company Profile

Labcorp Holdings, Inc engages in providing medical testing services. The company was founded on April 16, 2024 and is headquartered in Burlington, NC.